Coiled Therapeutics (COTX.F) Stock Overview

A clinical-stage oncology company, develops and commercialises clinical-stage oncology therapeutics in the United Kingdom and internationally. More details

COTX.F fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Has not reported any financial data

Shares are highly illiquid

Does not have a meaningful market cap ($64M)

COTX.F Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Coiled Therapeutics plc Competitors

Price History & Performance

Summary of share price highs, lows and changes for Coiled Therapeutics
Historical stock prices
Current Share Price	UK£0.14
52 Week High	UK£0.21
52 Week Low	UK£0.096
Beta	0
1 Month Change	50.41%
3 Month Change	-13.17%
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-87.92%

Recent updates

Shareholder Returns

	COTX.F	US Biotechs	US Market
7D	-14.7%	-2.9%	-2.8%
1Y	n/a	26.6%	22.8%

Return vs Industry: Insufficient data to determine how COTX.F performed against the US Biotechs industry.

Return vs Market: Insufficient data to determine how COTX.F performed against the US Market.

Price Volatility

Is COTX.F's price volatile compared to industry and market?
COTX.F volatility
COTX.F Average Weekly Movement	n/a
Biotechs Industry Average Movement	10.9%
Market Average Movement	7.2%
10% most volatile stocks in US Market	16.6%
10% least volatile stocks in US Market	3.1%

Stable Share Price: COTX.F's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine COTX.F's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
n/a	n/a	Sridhar Vempati	www.coiledtx.com/

Coiled Therapeutics plc, a clinical-stage oncology company, develops and commercialises clinical-stage oncology therapeutics in the United Kingdom and internationally. The company’s lead asset is AO-252, a first-in-class, small molecule inhibitor of TACC3, currently in a Phase I clinical trial for advanced solid tumours, including ovarian and prostate cancer. The company also offers a STAT-6 siRNA programme targeting immunology indications such as asthma, fibrosis, eczema, and allergic disease, with plans for assessment towards Phase I clinical trials.

Coiled Therapeutics plc Fundamentals Summary

How do Coiled Therapeutics's earnings and revenue compare to its market cap?
COTX.F fundamental statistics
Market cap	US$63.90m
Earnings (TTM)	US$0
Revenue (TTM)	n/a

n/a

P/E Ratio

n/a

P/S Ratio

Is COTX.F overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
COTX.F income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$0
Earnings	US$0

Last Reported Earnings

n/a

Next Earnings Date

n/a

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did COTX.F perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/06/07 11:40
End of Day Share Price	2026/06/02 00:00
Earnings	N/A
Annual Earnings	N/A

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Coiled Therapeutics plc is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Coiled Therapeutics plcOTCPK:COTX.F Stock Report